ER-Positive Breast Cancer: Addition of Adjuvant Ovarian Function Suppression to Tamoxifen in Premenopausal Patients

Development and Validation of a Novel TNM Staging N-Classification of Oral Cavity Squamous Cell Carcinoma

Utilizing Biomarkers to Optimize Treatment for Upper Gastrointestinal Cancers

Survival Benefit With Checkpoint Inhibitors Versus Chemotherapy is Modified by Brain Metastases in Patients With Recurrent Small-Cell Lung Cancer

Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease

ChatGPT's Limited Ability to Recommend Guideline-Based Cancer Treatments

Response Assessment of Post-Treatment Head and Neck Cancers to Determine Further Management Using NI-RADS (Neck Imaging Reporting and Data System): A Subgroup Analysis of a Randomized Controlled Trial

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, HER2-, BRCA1/2 Mutant Breast Cancer

ER-Positive Breast Cancer: Addition of Adjuvant Ovarian Function Suppression to Tamoxifen in Premenopausal Patients

header-info

Aug, 31, 2023

In an 8-year follow-up of a Korean phase III trial, investigators evaluated the effects of adding adjuvant ovarian function suppression to tamoxifen in premenopausal patients with ER-positive breast cancer, with a focus on the disease-free survival benefit.

Access the full article to read more here.